Cytek Biosciences Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019
Net Income	-12.15	2.58	0	3.22	-16.83
Depreciation & Amortization	9.23	5.66	1.24	0.6	0.31
Share-Based Compensation	22.05	16.6	6.59	0.61	0.27
Other Operating Activities	-13.85	-37.06	-6.2	-5.47	2.5
Operating Cash Flow	5.28	-12.23	4.63	15.16	-13.75
Operating Cash Flow Growth	-	-	-69.45%	-	-
Capital Expenditures	-4.83	-9.87	-4.36	-1.55	-0.97
Acquisitions	-45.13	0	-16.63	0	0
Change in Investments	-43.94	-46.04	0	0	0
Investing Cash Flow	-93.89	-55.91	-20.99	-1.55	-0.97
Share Issuance / Repurchase	-40.83	2.79	216.33	0.17	0.09
Debt Issued / Paid	-0.57	2.93	-2.77	2.77	0
Other Financing Activities	-0.42	-0.21	-	119.67	-
Financing Cash Flow	-41.81	5.51	213.56	122.61	0.09
Exchange Rate Effect	-1.45	-2.49	1.3	-0.59	-0.03
Net Cash Flow	-131.87	-65.12	198.5	135.63	-14.66
Free Cash Flow	0.45	-22.1	0.27	13.61	-14.72
Free Cash Flow Growth	-	-	-98.05%	-	-
Free Cash Flow Margin	0.24%	-13.47%	0.21%	14.66%	-25.43%
Free Cash Flow Per Share	0.00	-0.16	0.00	0.47	-0.70

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).